Using Oral Valacyclovir to Treat Patients With Refractory IC/BPS

Unknown statusPhase 1NCT05094414

View the official record on ClinicalTrials.gov

Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.

This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.

Brief summary (from the registry)

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a collective term referring to disorders which is characterized by lower urinary tract symptoms, including bladder pain/discomfort, frequent urination without evidence of bacterial infection. The etiology of IC/BPS is still uncertain, and most current treatment for IC/BPS are only symptoms control. Our previous study revealed Epstein-Barr virus (EBV) infection presented in the IC/BPS bladders and involved the pathogenesis. Hence, using anti-viral medication valacyclovir for the patients with IC/BPS might have clinical efficacy.

Study details

Official title: Urology Department, Hualien Tzu Chi Hospital, Hualien, Taiwan
Conditions: Pain, Chronic
Urge Incontinence
Overactive Bladder Syndrome
Quality of Life
Interventions: Drug: Valacyclovir
Sponsor: Buddhist Tzu Chi General Hospital
Collaborators: Ministry of Science and Technology, Taiwan; Hualien Tzu Chi General Hospital
Start date: 2021-07-01
Primary completion: 2022-02-28
Sex: All
Age range: from 18 Years to 80 Years
Results posted: No results posted in this snapshot
Countries: Taiwan
Total sites listed: 1

Eligibility criteria

Show eligibility criteria (verbatim from the registry)

Inclusion Criteria: * patients with IC/BPS Exclusion Criteria: * patients with neurogenic bladder * patients with bladder outlet obstruction * patients with lymphoma * patients with bacteria cystitis

Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05094414